Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of catalpol in preparation of medicine for treating ischemic cerebral apoplexy sequelae

A technology for ischemic stroke and sequelae, applied in the field of medicine, can solve problems such as aggravation

Inactive Publication Date: 2013-01-09
苏州玉森新药开发有限公司
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The sequelae of ischemic stroke can accompany the patient's continuous aggravation until death, which brings great pain to the patient and a great economic burden to the family
However, so far, there is no special effective drug treatment for ischemic stroke sequelae. Relatively speaking, traditional Chinese medicine has the advantages of less toxic and side effects, suitable for long-term use, and low cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of catalpol in preparation of medicine for treating ischemic cerebral apoplexy sequelae
  • Application of catalpol in preparation of medicine for treating ischemic cerebral apoplexy sequelae
  • Application of catalpol in preparation of medicine for treating ischemic cerebral apoplexy sequelae

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Influence on neurological deficit symptoms

[0018] 1.1 Purpose

[0019] A rat model of permanent cerebral ischemia injury with thread method was used to observe the effect of catalpol on the neurological deficit function of rats with cerebral ischemia injury to determine whether it has the effect of promoting the recovery of sequelae of ischemic stroke.

[0020] 1.2 Test materials

[0021] 1.2.1 Animal health SD male rats weighing 260-290g.

[0022] 1.2.2 Drugs

[0023] 1.2.2.1 Test drug

[0024] Catalpol, white or colorless powder, weighed 0.3g powder, dissolved to 100ml with deionized water, and administered 1ml / 100g body weight by intragastric administration.

[0025] 1.2.2.2 Positive drugs

[0026] Tianbaoning: Produced by Zhejiang Conba Pharmaceutical Co., Ltd., the clinical daily dosage is 6 tablets. Preparation method: Take 7 tablets, grind them into powder and dissolve them to 100ml with deionized water, and administer 1ml / 100g body weight by gavage.

[0027] Edara...

Embodiment 2

[0066] Example 2 Effect on pathological changes of neurons

[0067] 2.1 Purpose

[0068] To observe the effect of catalpol on the pathological changes of brain tissue neurons in rats with permanent cerebral ischemia injury in the early recovery period, to evaluate the effect of oral administration of catalpol on the early recovery period in rats with permanent cerebral ischemia injury, and whether it can promote neuron survival , Repair and structural integrity.

[0069] 2.2 Test materials

[0070] 2.2.1 Animals

[0071] Same as 1.2.1.

[0072] 2.2.2 Drugs and reagents

[0073] 2.2.2.1 Drugs

[0074] Same as 1.2.2

[0075] 2.2.2.2 Main reagents

[0076] Paraformaldehyde and glutaraldehyde are all domestic reagents and analytically pure.

[0077] 2.2.3 Main experimental equipment

[0078] Biological tissue automatic dehydrator (produced by Hubei Medical Electronic Instrument Factory, TS-12F); LEICA RM2235 rotary paraffin slicer (Germany); biological tissue spreader (produced by Hubei Medical E...

Embodiment 3

[0105] Example 3 Impact on energy metabolism disorders

[0106] 3.1 Purpose

[0107] A rat model of permanent cerebral ischemia injury was used to observe the effect of catalpol on brain energy metabolism disorders in rats with cerebral ischemia injury to determine whether it has the ability to enhance brain energy, reduce acidosis, and improve brain energy metabolism disorders. effect.

[0108] 3.2 Test materials

[0109] 3.2.1 Animals

[0110] Same as 1.2.1.

[0111] 3.2.2 Drugs and reagents

[0112] 3.2.2.1 Test drug

[0113] Same as 1.2.2.1

[0114] 3.2.2.2 Positive drugs

[0115] Same as 1.2.2.2.

[0116] 3.2.2.3 Reagents

[0117] 3.2.2.3.1 Protein, lactic acid (Lac), pyruvate (Pyru) and ATPase kits were purchased from Nanjing Jiancheng Institute of Bioengineering.

[0118] 3.2.2.3.2 Protein, lactic acid (Lac), pyruvate (Pyru) and ATPase kits were purchased from Nanjing Jiancheng Institute of Bioengineering.

[0119] 3.2.3. Main experimental instruments

[0120] HITACHI U-2000 Ultraviolet-V...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel application of catalpol, which belongs to the medicine technical field, and concretely relates to an application of catalpol in preparation of medicine for treating ischemic cerebral apoplexy sequelae, and the application of catalpol in preparation of medicine for improving neurologic function defective symptom of ischemic cerebral apoplexy sequelae. Catalpol has the effects for mitigating the change of neuron pathology and improving the energy metabolic disturbance in brain tissue.

Description

Technical field [0001] The invention discloses a new use of catalpol, in particular the application of catalpol in the preparation of drugs for the treatment of sequelae of ischemic stroke, and the application of the preparation of drugs for improving the symptoms of neurological deficits in the sequelae of ischemic stroke. Medical technology field. Background technique [0002] The sequelae of ischemic stroke refers to the focal symptoms of different degrees of hemiplegia, aphasia, and mild disturbance of consciousness left behind after treatment for patients with acute cerebral infarction. Stroke is a common and frequently-occurring disease that endangers human life and health. There are about 15 million stroke patients worldwide each year, of which ischemic stroke accounts for a considerable proportion (75%-85%). In the large number of cases of ischemic stroke reported in the past, only a few patients have fully recovered, and most patients have residual neurological dysfunct...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P25/28
Inventor 玄振玉
Owner 苏州玉森新药开发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com